April 9, 2025

Alpenglow Biosciences

Seattle-based Alpenglow Biosciences named Blandine Merino and Mike Rice to its advisory board. Merino has over 20 years of experience driving product development, business operations, and strategy at companies like Guardant Health, Freenome, and Agilent. She specializes in NGS, digital pathology, and AI-powered cancer detection. At Guardant Health, she led cross-functional teams to expand the use of NGS testing in clinical trials, partnering with over 50 biopharma companies to advance cancer drug development. As VP of business development at Freenome, she developed and executed a strategy that accelerated the launch of a multi-analyte, machine-learning-powered early cancer detection test. She established co-development programs with academic medical centers and biopharma partners and led initiatives for licensing and global expansion. Merino is also the founder of Bio2Market, a consulting firm supporting life sciences and AI-driven companies. She holds an M.S. in Molecular Biology from the University of Paris-Saclay and an M.S. in Engineering from ISA Graduate School in Bioengineering. Rice is a veteran life science tools executive with more than 17 years of public company leadership experience. As former chairman and CEO of BioLife Solutions he led the transformation of the company from a small operation with fewer than 10 employees into a critical supplier of proprietary cell processing reagents with over 500 employees. Alpenglow is a venture-backed company focused on accelerating drug development and improving clinical diagnostics with AI-enabled 3D spatial imaging technology.